Abstract
dc:description.abstractThe number of Americans who are diagnosed with obesity and type 2 diabetes mellitus has been on a steady incline for at least the past 20 years. An increase in the number of patients struggling with these diseases comes with what seems like a correlating increase in the costs of healthcare. Significant innovations have been improving the quality of life and treating obesity and diabetes since the 1960s. However, with the increases in costs of care, it is important to understand the cost efficacy of newer medications periodically to gain a comprehensive understanding of the cost efficacy of these medications in improving the quality of life and health of these patients. Therefore, this paper will focus on the cost efficacy of Semaglutide, a new drug that functions as a glucagon-like peptide-1 (GLP-1) agonist. Other drugs and procedures on the market, such as Liraglutide, Contrave, Orlistat, phentermine-topiramate, and gastric bypass surgery, will be used as a comparison for Semaglutide. Based on a year's supply of the drug and the percentage of weight lost, the cost to lose weight was found. Then, based on the percent weight lost, the projected savings in medical care expenditure were calculated. This results in a ratio that compares the benefits to the cost of the medication. As a result, Semaglutide was effective in reducing weight; however, the price of the drug makes it less cost-efficient than other options on the market. However, it still has its place as it is still more cost-efficient than other medications, and it also has a different mechanism of action, which helps prove useful for certain types of patients.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Luo, Andrew
- Advisors dc:contributor.advisor
-
- Offner, Gwynneth
- Gong, Haiyan
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/51820